|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: STRN |
Gene summary for STRN |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | STRN | Gene ID | 6801 |
| Gene name | striatin | |
| Gene Alias | PPP2R6A | |
| Cytomap | 2p22.2 | |
| Gene Type | protein-coding | GO ID | GO:0007043 | UniProtAcc | O43815 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6801 | STRN | P2T-E | Human | Esophagus | ESCC | 1.09e-26 | 4.68e-01 | 0.1177 |
| 6801 | STRN | P4T-E | Human | Esophagus | ESCC | 2.97e-07 | 1.42e-01 | 0.1323 |
| 6801 | STRN | P5T-E | Human | Esophagus | ESCC | 6.20e-08 | 1.49e-01 | 0.1327 |
| 6801 | STRN | P8T-E | Human | Esophagus | ESCC | 1.12e-13 | 1.61e-01 | 0.0889 |
| 6801 | STRN | P9T-E | Human | Esophagus | ESCC | 2.10e-05 | 1.22e-01 | 0.1131 |
| 6801 | STRN | P10T-E | Human | Esophagus | ESCC | 2.91e-11 | 1.72e-01 | 0.116 |
| 6801 | STRN | P12T-E | Human | Esophagus | ESCC | 2.67e-10 | 1.36e-01 | 0.1122 |
| 6801 | STRN | P15T-E | Human | Esophagus | ESCC | 4.57e-08 | 2.41e-01 | 0.1149 |
| 6801 | STRN | P16T-E | Human | Esophagus | ESCC | 1.41e-06 | 9.90e-02 | 0.1153 |
| 6801 | STRN | P17T-E | Human | Esophagus | ESCC | 1.30e-03 | 1.36e-01 | 0.1278 |
| 6801 | STRN | P20T-E | Human | Esophagus | ESCC | 2.47e-10 | 1.05e-01 | 0.1124 |
| 6801 | STRN | P21T-E | Human | Esophagus | ESCC | 8.24e-17 | 1.76e-01 | 0.1617 |
| 6801 | STRN | P22T-E | Human | Esophagus | ESCC | 3.51e-07 | 1.95e-01 | 0.1236 |
| 6801 | STRN | P23T-E | Human | Esophagus | ESCC | 2.21e-14 | 3.34e-01 | 0.108 |
| 6801 | STRN | P24T-E | Human | Esophagus | ESCC | 3.19e-08 | 1.25e-01 | 0.1287 |
| 6801 | STRN | P26T-E | Human | Esophagus | ESCC | 4.74e-14 | 2.40e-01 | 0.1276 |
| 6801 | STRN | P27T-E | Human | Esophagus | ESCC | 3.26e-12 | 1.54e-01 | 0.1055 |
| 6801 | STRN | P28T-E | Human | Esophagus | ESCC | 2.17e-07 | 2.17e-01 | 0.1149 |
| 6801 | STRN | P30T-E | Human | Esophagus | ESCC | 1.02e-10 | 5.67e-01 | 0.137 |
| 6801 | STRN | P31T-E | Human | Esophagus | ESCC | 1.37e-10 | 1.26e-01 | 0.1251 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00160557 | Cervix | CC | Wnt signaling pathway | 98/2311 | 444/18723 | 4.82e-09 | 4.65e-07 | 98 |
| GO:01987387 | Cervix | CC | cell-cell signaling by wnt | 98/2311 | 446/18723 | 6.16e-09 | 5.58e-07 | 98 |
| GO:00452169 | Cervix | CC | cell-cell junction organization | 53/2311 | 200/18723 | 3.83e-08 | 2.53e-06 | 53 |
| GO:00343298 | Cervix | CC | cell junction assembly | 88/2311 | 420/18723 | 3.42e-07 | 1.38e-05 | 88 |
| GO:00163587 | Cervix | CC | dendrite development | 58/2311 | 243/18723 | 4.52e-07 | 1.76e-05 | 58 |
| GO:004854510 | Cervix | CC | response to steroid hormone | 74/2311 | 339/18723 | 5.71e-07 | 2.09e-05 | 74 |
| GO:00070439 | Cervix | CC | cell-cell junction assembly | 39/2311 | 146/18723 | 1.86e-06 | 5.94e-05 | 39 |
| GO:00305229 | Cervix | CC | intracellular receptor signaling pathway | 60/2311 | 265/18723 | 1.89e-06 | 5.97e-05 | 60 |
| GO:00432978 | Cervix | CC | apical junction assembly | 24/2311 | 78/18723 | 1.36e-05 | 2.73e-04 | 24 |
| GO:00323556 | Cervix | CC | response to estradiol | 34/2311 | 141/18723 | 8.19e-05 | 1.11e-03 | 34 |
| GO:01201927 | Cervix | CC | tight junction assembly | 21/2311 | 74/18723 | 1.69e-04 | 2.00e-03 | 21 |
| GO:01201937 | Cervix | CC | tight junction organization | 22/2311 | 80/18723 | 1.97e-04 | 2.26e-03 | 22 |
| GO:00708306 | Cervix | CC | bicellular tight junction assembly | 18/2311 | 70/18723 | 1.69e-03 | 1.29e-02 | 18 |
| GO:00713839 | Cervix | CC | cellular response to steroid hormone stimulus | 40/2311 | 204/18723 | 1.93e-03 | 1.42e-02 | 40 |
| GO:00305188 | Cervix | CC | intracellular steroid hormone receptor signaling pathway | 25/2311 | 116/18723 | 3.59e-03 | 2.30e-02 | 25 |
| GO:0045216 | Colorectum | AD | cell-cell junction organization | 80/3918 | 200/18723 | 5.57e-10 | 4.58e-08 | 80 |
| GO:0034329 | Colorectum | AD | cell junction assembly | 136/3918 | 420/18723 | 2.02e-08 | 1.15e-06 | 136 |
| GO:0007043 | Colorectum | AD | cell-cell junction assembly | 57/3918 | 146/18723 | 4.18e-07 | 1.61e-05 | 57 |
| GO:0071383 | Colorectum | AD | cellular response to steroid hormone stimulus | 73/3918 | 204/18723 | 6.31e-07 | 2.24e-05 | 73 |
| GO:0030522 | Colorectum | AD | intracellular receptor signaling pathway | 87/3918 | 265/18723 | 3.69e-06 | 1.03e-04 | 87 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| STRN | SNV | Missense_Mutation | rs766580191 | c.799N>A | p.Val267Ile | p.V267I | O43815 | protein_coding | tolerated(0.36) | benign(0.009) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| STRN | SNV | Missense_Mutation | c.1106N>T | p.Ser369Leu | p.S369L | O43815 | protein_coding | tolerated(0.26) | benign(0.003) | TCGA-BH-A0BP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| STRN | insertion | Nonsense_Mutation | novel | c.376_377insGTGTACAATACCTAGTTATTCTCAGTATGTAATAGTT | p.Asn126SerfsTer11 | p.N126Sfs*11 | O43815 | protein_coding | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| STRN | SNV | Missense_Mutation | novel | c.1486N>A | p.Ala496Thr | p.A496T | O43815 | protein_coding | tolerated(0.11) | benign(0.01) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| STRN | SNV | Missense_Mutation | c.1379N>A | p.Arg460Lys | p.R460K | O43815 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-MY-A5BD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| STRN | SNV | Missense_Mutation | c.240N>C | p.Gln80His | p.Q80H | O43815 | protein_coding | deleterious(0.01) | probably_damaging(0.986) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| STRN | SNV | Missense_Mutation | c.988N>G | p.Thr330Ala | p.T330A | O43815 | protein_coding | tolerated(0.57) | benign(0.003) | TCGA-AA-3966-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| STRN | SNV | Missense_Mutation | c.913G>T | p.Gly305Cys | p.G305C | O43815 | protein_coding | deleterious(0) | possibly_damaging(0.827) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| STRN | SNV | Missense_Mutation | rs748865330 | c.836N>A | p.Arg279Gln | p.R279Q | O43815 | protein_coding | tolerated(0.44) | benign(0.18) | TCGA-AZ-4313-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| STRN | SNV | Missense_Mutation | novel | c.1434N>T | p.Leu478Phe | p.L478F | O43815 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |